Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy

Cong Dai, Wei-Xin Liu, Min Jiang, Ming-Jun Sun, Cong Dai, Wei-Xin Liu, Min Jiang, Ming-Jun Sun

Abstract

Aim: To assess the endoscopic activity and Clinical activity after a one-year period of infliximab therapy and to evaluate the association between mucosal healing and need for retreatment after stopping infliximab in patients with Inflammatory bowel disease (IBD).

Methods: The data from 109 patients with Crohn's disease (CD) and 107 patients with Ulcerative colitis (UC) received one-year infliximab were assessed. The primary endpoint of the study was the proportion of clinical remission, mucosal healing and full remission in IBD after the one-year period of maintenance infliximab therapy. The secondary endpoint was the frequency of relapses in the next year.

Results: A total of 84.4% (92/109) CD patients and 81.3% (87/107) UC patients achieved clinical remission, 71.56% (78/109) of CD patients and 69.16% (74/107) of UC patients achieved mucosal healing, 56.88% (62/109) of CD patients and 54.21% (58/107) of UC patients achieved full remission at the end of the year of infliximab therapy. Infliximab therapy was restarted in the 10.19% (22/216) patients (13 CD, 9 UC) who achieved mucosal healing, and 13.89% (30/216) patients (18 CD, 12 UC) who achieved clinical remission and 6.48% (14/216) patients (8 CD, 6 UC) who achieved full remission had to be retreated within the next year. Neither clinical remission nor mucosal healing was associated with the time to restarting Infliximab therapy in IBD.

Conclusion: Mucosal healing did not predict sustained clinical remission in patients with IBD in whom the infliximab therapies had been stopped. And stopping or continuing infliximab therapy may be determined by assessing the IBD patient's general condition and the clinical activity.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1
Kaplan-Meier analysis using Log-Rank and Breslow tests (clinical remission or mucosal healing was not associated with the time to restarting infliximab therapy in Crohn’s disease).
Figure 2
Figure 2
Kaplan-Meier analysis using Log-Rank and Breslow tests (clinical remission or mucosal healing was not associated with the time to restarting infliximab therapy in Ulcerative colitis).

References

    1. Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641–1657.
    1. Wardle RA, Mayberry JF (2014) Patient knowledge in inflammatory bowel disease: the Crohn’s and Colitis Knowledge Score. Eur J Gastroenterol Hepatol 26: 1–5.
    1. Ye L, Cao Q, Cheng J (2013) Review of Inflammatory Bowel Disease in China. ScientificWorldJournal 2013: 296470.
    1. Mulder DJ, Noble AJ, Justinich CJ, Duffin JM (2013) A tale of two diseases: The history of inflammatory bowel disease. J Crohns Colitis.
    1. Speight RA, Mansfield JC (2013) Drug advances in inflammatory bowel disease. Clin Med 13: 378–382.
    1. Danese S (2012) New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61: 918–932.
    1. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF (2010) Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 7: 15–29.
    1. Armuzzi A, Van Assche G, Reinisch W, Pineton de Chambrun G, Griffiths A, et al. (2012) Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. J Crohns Colitis 6: 492–502.
    1. Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, et al. (2004) Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 60: 505–512.
    1. Dave M, Loftus EV Jr (2012) Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y) 8: 29–38.
    1. Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317: 1625–1629.
    1. Rutgeerts P, Vermeire S, Van Assche G (2007) Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 56: 453–455.
    1. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462–2476.
    1. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, et al. (2012) Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142: 63–70 e65; quiz e31.
    1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, et al. (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359: 1541–1549.
    1. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130: 323–333; quiz 591.
    1. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, et al. (2009) Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 58: 492–500.
    1. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, et al. (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 Suppl A: 5A–36A.
    1. Best WR, Becktel JM, Singleton JW, Kern F Jr (1976) Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 70: 439–444.
    1. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, et al. (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126: 402–413.
    1. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, et al. (2006) Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 63: 433–442; quiz 464.
    1. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, et al. (2009) Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 15: 1295–1301.
    1. Froslie KF, Jahnsen J, Moum BA, Vatn MH (2007) Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133: 412–422.
    1. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, et al. (2010) Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 138: 463–468; quiz e410–461.
    1. Ananthakrishnan AN, Korzenik JR, Hur C (2013) Can Mucosal Healing Be a Cost-effective Endpoint for Biologic Therapy in Crohn’s Disease? A Decision Analysis. Inflamm Bowel Dis 19: 37–44.
    1. Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Ostergaard Thomsen O, et al. (2012) Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 47: 518–527.
    1. Freeman HJ (2010) Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol 16: 15–20.
    1. Laharie D, Filippi J, Roblin X, Nancey S, Chevaux JB, et al. (2013) Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther 37: 998–1004.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren